The upcoming presentations focus on expanding the clinical understanding of migraine beyond mere attack frequency. For the approved treatment Vyepti (eptinezumab), new analyses from the RESOLUTION and SUNRISE trials examine patient-centered outcomes, including workplace productivity, acute medication reliance, and the psychological impact of chronic migraine and medication-overuse headache.
In section Releases
Lundbeck unveils new migraine data at EAN 2026
Lundbeck is set to present fresh clinical findings on its migraine portfolio at the European Academy of Neurology Congress in Geneva, taking place June 27–30. The company will showcase data for its established therapy, Vyepti, alongside primary results from the Phase IIb PROCEED trial for the investigational candidate, bocunebart.
Lundbeck is also placing a spotlight on bocunebart, a monoclonal antibody designed to inhibit the pituitary adenylate cyclase-activating polypeptide (PACAP) pathway. As a late-breaker presentation, the PROCEED trial data will offer insight into whether this distinct mechanism can provide relief for patients who have failed to respond to previous preventive treatments. According to Dr. Andrew Blumenfeld of Cedars Sinai Los Angeles, this research represents a critical step in addressing the needs of patients who remain underserved by current therapeutic options.
Comments (0)
No comments yet. Be the first!